Zusammenfassung
Hintergrund
Die Molekularpathologie dient zunehmend der Therapiesteuerung in der Onkologie. Etwa 25 % aller hepatozellulären Karzinome (HCCs) und 50 % der Cholangiokarzinome (CCAs) weisen bekannte krebsrelevante Mutationen auf, deren Einfluss auf die Behandlung dieser Tumoren noch nicht ausreichend verstanden ist.
Ziel der Arbeit
Die Evaluation der aktuellen Literatur über die molekularpathologischen Fortschritte beim HCC/CCA und deren möglicher Einfluss auf die onkologische Chirurgie.
Material und Methoden
Zunächst erfolgte eine Zusammenfassung der in PubMed und clinitrials.gov verfügbaren Literatur über die aktuell bekannten molekularen Biomarker beim HCC/CCA. Anhand dieser Daten wird der mögliche Einfluss dieser Biomarker auf die onkologische Chirurgie diskutiert.
Schlussfolgerung
Molekularpathologische Untersuchungen können zur Unterstützung der Tumortypisierung und Dignitätsbestimmung von HCCs/CCAs eingesetzt werden. Prädiktive molekulare Biomarker konnten sich in der regulären Diagnostik noch nicht etablieren, können aber zur erweiterten Therapieplanung eingesetzt werden.
Abstract
Background
Molecular pathology is increasingly being used to guide treatment in oncology. Approximately 25% of all hepatocellular carcinomas (HCC) and 50% of cholangiocarcinomas (CCA) present with known cancer-relevant mutations; however, the impact of the mutations on the treatment of these tumors is not yet sufficiently understood.
Purpose
To evaluate the current literature on molecular pathological advances in HCC/CCA and the potential impact on oncological surgery.
Material and methods
A comprehensive search of the available literature on currently known molecular biomarkers in HCC/CCA was performed in PubMed and clinitrials.gov. Following review, the potential impact of these biomarkers on oncological surgery was analyzed and is discussed.
Conclusion
Molecular pathological investigations can be used to support the classification of tumors and to determine the dignity of HCC/CCA. Predictive molecular biomarkers are not yet established in routine diagnostics but can be used to individualize advanced oncological treatment.
Literatur
Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW et al (2019) EGFR mutation is associated with short progression free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy. Cancer Res Treat 51(2):493–501
Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C et al (2017) The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 3(12):1683–1691
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833
Nöpel-Dünnebacke S, Conradi L‑C, Reinacher-Schick A, Ghadimi M (2020) Therapeutic relevance of molecular markers in colorectal cancer. Onkologe 26:685–697
Duffy M, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E et al (2017) Clinical use of biomarkers in breast cancer: updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer 75:284–298
Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M et al (2021) Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. https://doi.org/10.1016/j.jhep.2021.04.049
Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599–616
Boyault S, Rickman DS, De Reyniès A, Balabaud C, Rebouissou S, Jeannot E et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1):42–52
Lee J‑S, Heo J, Libbrecht L, Chu I‑S, Kaposi-Novak P, Calvisi DF et al (2006) A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12(4):410–416
Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B et al (2011) MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 140(5):1618–1628.e16
von Felden J, Villanueva A (2020) Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl 26(6):823–831
Solinas A, Calvisi DF (2016) Programmed death ligand 1 expression in hepatocellular carcinoma: a prognostic marker and therapeutic target for liver cancer? Hepatology 64(6):1847–1849
Li X‑S, Li J‑W, Li H, Jiang T (2020) Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Biosci Rep 40(4):BSR20200459
Heitzer E, Haque IS, Roberts CE, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20(2):71–88
von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A (2020) Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut 69(11):2025–2034
Chen VL, Xu D, Wicha MS, Lok AS, Parikh ND (2020) Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: a systematic review. Clin Gastroenterol Hepatol 18(13):2879–2902.e9
Chen J, Parkin D, Chen Q, Lu J, Shen Q, Zhang B et al (2003) Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 10(4):204–209
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69(1):182–236
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A et al (2018) Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 154(6):1706–1718.e1
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR et al (2009) α‑fetoprotein, des‑γ carboxyprothrombin, and lectin-bound α‑fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68(2):723–750
Pons F, Varela M, Llovet JM (2005) Staging systems in hepatocellular carcinoma. HPB 7(1):35–41
Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T et al (2021) Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18(5):293–313
Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC (2009) Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 1:Cd1199
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ et al (2015) Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148(7):1383–1391.e6
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16(13):1344–1354
Renner P, Da Silva T, Schnitzbauer AA, Verloh N, Schlitt HJ, Geissler EK (2021) Hepatocellular carcinoma progression during bridging before liver transplantation. BJS Open 5(2):zrab5
Singal AG, Pillai A, Tiro J (2014) Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 11(4):e1001624
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A et al (2016) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64(5):1090–1098
Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R et al (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2(8):565–575
Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L et al (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60(5):1697–1707
Struecker B, Morguel H, Pascher A (2020) Cholangiokarzinome–aktuelle Therapiestandards. Onkologe 26(3):238–245
Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17(9):557–588
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15(2):95
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19‑9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207
Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004) Utility of serum CA19‑9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 10(3):427–432
Marrero JA (2014) Biomarkers in cholangiocarcinoma. Clin Liver Dis (Hoboken) 3(5):101–103
Macias RIR, Kornek M, Rodrigues PM, Paiva NA, Castro RE, Urban S et al (2019) Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int 39(Suppl 1):108–122
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C et al (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223–238
Liang Z, Liu X, Zhang Q, Wang C, Zhao Y (2016) Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis 48(10):1227–1232
Zhou J, Liu Z, Yang S, Li X (2017) Identification of microRNAs as biomarkers for cholangiocarcinoma detection: a diagnostic meta-analysis. Clin Res Hepatol Gastroenterol 41(2):156–162
Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y et al (2011) Real-time PCR-based analysis of the human bile microRNAome identifies miR‑9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6(8):e23584
Al Ustwani O, Iancu D, Yacoub R, Iyer R (2012) Detection of circulating tumor cells in cancers of biliary origin. J Gastrointest Oncol 3(2):97–104
Yang JD, Campion MB, Liu MC, Chaiteerakij R, Giama NH, Ahmed Mohammed H et al (2016) Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology 63(1):148–158
Parsa N, Khashab MA (2019) The role of peroral cholangioscopy in evaluating indeterminate biliary strictures. Clin Endosc 52(6):556
Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO et al (2015) MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS ONE 10(10):e139305
Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL et al (2015) MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6(8):5932–5946
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A (2019) Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int 39(Suppl 1):98–107
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D (2016) Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(Suppl 5):v28–v37
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M et al (2015) Genomic spectra of biliary tract cancer. Nat Genet 47(9):1003–1010
Nepal C, O’Rourke CJ, Oliveira D, Taranta A, Shema S, Gautam P et al (2018) Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology 68(3):949–963
Ruys AT, Groot Koerkamp B, Wiggers JK, Klümpen HJ, ten Kate FJ, van Gulik TM (2014) Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 21(2):487–500
Liu CH, Huang Q, Jin ZY, Xie F, Zhu CL, Liu Z et al (2018) Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. J Cancer Res Ther 14(1):220–225
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1):88–98.e3 (quiz e14)
Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB et al (2018) Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg 267(5):797–805
Frosio F, Mocchegiani F, Conte G, Bona ED, Vecchi A, Nicolini D et al (2019) Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: review of the literature. World J Gastrointest Surg 11(6):279–286
Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I et al (2018) Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg 105(7):848–856
Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG et al (2018) Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multi-institutional study from the US Extrahepatic Biliary Malignancy Consortium. World J Surg 42(9):2919–2929
Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D et al (2015) Chemotherapy for surgically resected intrahepatic cholangiocarcinoma. Ann Surg Oncol 22(11):3716–3723
Malka D, Edeline J (2019) Adjuvant capecitabine in biliary tract cancer: a standard option? Lancet Oncol 20(5):606–608
Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J et al (2019) Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol 37(12):1015–1027
Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen H‑J et al (2015) Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA‑1 trial)-a randomized, multidisciplinary, multinational phase III trial. BMC Cancer 15(1):564
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM et al (2015) SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622
Jia AY, Wu JX, Zhao YT, Li YX, Wang Z, Rong WQ et al (2015) Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma. J Gastrointest Oncol 6(2):126–133
Plentz RR, Malek NP (2016) Systemic therapy of cholangiocarcinoma. Visc Med 32(6):427–430
Lowery MA, Goff LW, Keenan BP, Jordan E, Wang R, Bocobo AG et al (2019) Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. Cancer 125(24):4426–4434
Abou-Alfa G, Mercade TM, Javle M, Kelley R, Lubner S, Adeva J et al (2019) ClarIDHy: a global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation. Ann Oncol 30:v872–v873
Lowery MA, Abou-Alfa GK, Burris H (2017) Phase 1 study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 132(2):3
Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ et al (2018) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol 36(3):276–282
Yamamoto K, Ueno T, Kawaoka T, Hazama S, Fukui M, Suehiro Y et al (2005) MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25(5):3575–3579
Guo Y, Feng K, Liu Y, Wu Z, Dai H, Yang Q et al (2018) Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers. Clin Cancer Res 24(6):1277–1286
Danksagung
Die Autoren danken Herrn Bernhard-Christian Münch für die Hilfe beim Erstellen des Manuskriptes.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M.A. Juratli, B. Struecker, S. Katou, M. H. Morguel und A. Pascher geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
I. Gockel, Leipzig
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Juratli, M.A., Struecker, B., Katou, S. et al. Einfluss der Molekularpathologie auf die onkologische Chirurgie von Leber- und Gallengangstumoren. Chirurg 92, 1003–1010 (2021). https://doi.org/10.1007/s00104-021-01495-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-021-01495-6
Schlüsselwörter
- Personalisierte Medizin
- Hepatozelluläres Karzinom
- Cholangiokarzinome
- Onkologische Chirurgie
- Flüssigbiopsie